RECRUITINGINTERVENTIONAL

Long-term COVID and Rehabilitation

Evaluating the Long-term Health Consequences of COVID-19 and Rehabilitation Therapies to Speed Convalescence

About This Trial

The proposed focuses on improving both morbidity and mortality in older Veterans and those recovering from COVID-19 by developing rehabilitation therapies to augment vascular endothelial function by combating the oxidative stress and inflammation associated with aging and further induced by COVID-19. The investigators expected outcomes will have an important positive impact because they will provide scientifically sound recommendations for rehabilitation to improve vascular endothelial function and minimize the long-term consequences of COVID-19.

Who May Be Eligible (Plain English)

Who May Qualify: - 50 years of age or greater - Long-COVID and COVID-recovered patients must have SARS-CoV-19 positive test near the time of COVID-19 diagnosis - Long-COVID and COVID-recovered patients must be 3-12 months post-initial COVID-19 diagnosis - Ability to sign willing to sign a consent form Who Should NOT Join This Trial: - BMI \>45 kg/m2 - Unstable (\<6 months) or severe coronary artery disease (CAD-RADS score = 4A), peripheral artery disease (Ankle Brachial Index \<0.40), cerebrovascular disease (identified by previous stroke in last 12 months), severe COPD (=Stage III), uncontrolled hypertension (\>160/100 mmHg), chronic kidney disease requiring dialysis, severe renal insufficiency (creatinine clearance \<30 by the Cockcroft-Gault formula), Alzheimer's disease, dementia - Orthopedic limitations that would prohibit exercise - \[Current smokers and individuals that stopped smoking in the last 10 years\] - Already taking Mito-Q or unwilling to cease dietary supplements for participation - Any other condition or event considered exclusionary by the PIs or a physician Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * 50 years of age or greater * Long-COVID and COVID-recovered patients must have SARS-CoV-19 positive test near the time of COVID-19 diagnosis * Long-COVID and COVID-recovered patients must be 3-12 months post-initial COVID-19 diagnosis * Ability to sign informed consent Exclusion Criteria: * BMI \>45 kg/m2 * Unstable (\<6 months) or severe coronary artery disease (CAD-RADS score = 4A), peripheral artery disease (Ankle Brachial Index \<0.40), cerebrovascular disease (identified by previous stroke in last 12 months), severe COPD (=Stage III), uncontrolled hypertension (\>160/100 mmHg), chronic kidney disease requiring dialysis, severe renal insufficiency (creatinine clearance \<30 by the Cockcroft-Gault formula), Alzheimer's disease, dementia * Orthopedic limitations that would prohibit exercise * \[Current smokers and individuals that stopped smoking in the last 10 years\] * Already taking Mito-Q or unwilling to cease dietary supplements for participation * Any other condition or event considered exclusionary by the PIs or a physician

Treatments Being Tested

DIETARY_SUPPLEMENT

Mitoquinone

Mito-Q is a supplement that targets mitochondrial function. Linking a triphenyl-phosphonium cation to coenzyme-Q, to produce Mito-Q, results in a lipophilic compound, which, due to the large mitochondrial membrane potential, selectively accumulates within mitochondria. This targeted antioxidant approach results in 50- to 100-fold more Mito-Q accumulation compared to non-targeted antioxidant delivery.

DIETARY_SUPPLEMENT

Placebo

A placebo will be used in combination with exercise rehabilitation allowing for a double blinded placebo controlled design.

Locations (1)

VA Salt Lake City Health Care System, Salt Lake City, UT

Salt Lake City, Utah, United States